| Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes DP Steensma, R Bejar, S Jaiswal, RC Lindsley, MA Sekeres, ... Blood, The Journal of the American Society of Hematology 126 (1), 9-16, 2015 | 2057 | 2015 |
| Hoffbrand's essential haematology V Hoffbrand, G Collins, J Loke John Wiley & Sons, 2024 | 1940 | 2024 |
| MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients AD Pardanani, RL Levine, T Lasho, Y Pikman, RA Mesa, M Wadleigh, ... Blood 108 (10), 3472-3476, 2006 | 1358 | 2006 |
| Acute myeloid leukemia ontogeny is defined by distinct somatic mutations RC Lindsley, BG Mar, E Mazzola, PV Grauman, S Shareef, SL Allen, ... Blood, The Journal of the American Society of Hematology 125 (9), 1367-1376, 2015 | 1064 | 2015 |
| Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials J Bohlius, K Schmidlin, C Brillant, G Schwarzer, S Trelle, J Seidenfeld, ... The Lancet 373 (9674), 1532-1542, 2009 | 738 | 2009 |
| TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients R Bejar, A Lord, K Stevenson, M Bar-Natan, A Pérez-Ladaga, J Zaneveld, ... Blood, The Journal of the American Society of Hematology 124 (17), 2705-2712, 2014 | 655 | 2014 |
| The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes DP Steensma, GW Dewald, TL Lasho, HL Powell, RF McClure, RL Levine, ... Blood 106 (4), 1207-1209, 2005 | 654 | 2005 |
| Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes R Bejar, KE Stevenson, BA Caughey, O Abdel-Wahab, DP Steensma, ... Journal of clinical oncology 30 (27), 3376-3382, 2012 | 576 | 2012 |
| Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation R Bejar, KE Stevenson, B Caughey, RC Lindsley, BG Mar, P Stojanov, ... Journal of clinical oncology 32 (25), 2691-2698, 2014 | 479 | 2014 |
| Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial DP Steensma, MR Baer, JL Slack, R Buckstein, LA Godley, ... Journal of clinical oncology 27 (23), 3842-3848, 2009 | 466 | 2009 |
| Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms O Wolach, RS Sellar, K Martinod, D Cherpokova, M McConkey, ... Science translational medicine 10 (436), eaan8292, 2018 | 424 | 2018 |
| Bone marrow niches in haematological malignancies S Méndez-Ferrer, D Bonnet, DP Steensma, RP Hasserjian, IM Ghobrial, ... Nature Reviews Cancer 20 (5), 285-298, 2020 | 410 | 2020 |
| Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes DA Sallman, AE DeZern, G Garcia-Manero, DP Steensma, GJ Roboz, ... Journal of Clinical Oncology 39 (14), 1584-1594, 2021 | 401 | 2021 |
| A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia RA Mesa, DP Steensma, A Pardanani, CY Li, M Elliott, SH Kaufmann, ... Blood, The Journal of the American Society of Hematology 101 (7), 2534-2541, 2003 | 401 | 2003 |
| The public repository of xenografts enables discovery and randomized phase II-like trials in mice EC Townsend, MA Murakami, A Christodoulou, AL Christie, J Köster, ... Cancer cell 29 (4), 574-586, 2016 | 349 | 2016 |
| The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis RA Mesa, S Schwager, D Radia, A Cheville, K Hussein, J Niblack, ... Leukemia research 33 (9), 1199-1203, 2009 | 287 | 2009 |
| SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS L Malcovati, K Stevenson, E Papaemmanuil, D Neuberg, R Bejar, ... Blood, The Journal of the American Society of Hematology 136 (2), 157-170, 2020 | 286 | 2020 |
| The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates A Tefferi, TL Lasho, SM Schwager, DP Steensma, RA Mesa, CY Li, ... British journal of haematology 131 (3), 320-328, 2005 | 280 | 2005 |
| Clinical consequences of clonal hematopoiesis of indeterminate potential DP Steensma Hematology 2014, the American Society of Hematology Education Program Book …, 2018 | 270 | 2018 |
| SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value MM Patnaik, TL Lasho, JM Hodnefield, RA Knudson, RP Ketterling, ... Blood, The Journal of the American Society of Hematology 119 (2), 569-572, 2012 | 258 | 2012 |
Mikkael SekeresProfessor of Medicine, Sylvester Comprehensive Cancer Center, University of MiamiVerified email at med.miami.edu
